ATE339223T1 - Kombinierte impfstoffzusammensetzungen - Google Patents

Kombinierte impfstoffzusammensetzungen

Info

Publication number
ATE339223T1
ATE339223T1 AT99914473T AT99914473T ATE339223T1 AT E339223 T1 ATE339223 T1 AT E339223T1 AT 99914473 T AT99914473 T AT 99914473T AT 99914473 T AT99914473 T AT 99914473T AT E339223 T1 ATE339223 T1 AT E339223T1
Authority
AT
Austria
Prior art keywords
vaccine compositions
combined vaccine
combined
compositions
vaccine
Prior art date
Application number
AT99914473T
Other languages
English (en)
Inventor
Jean Stephenne
Martine Anne Cecil Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805105.5A external-priority patent/GB9805105D0/en
Priority claimed from GBGB9813561.9A external-priority patent/GB9813561D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE339223T1 publication Critical patent/ATE339223T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99914473T 1998-03-09 1999-03-04 Kombinierte impfstoffzusammensetzungen ATE339223T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805105.5A GB9805105D0 (en) 1998-03-09 1998-03-09 Novel composition
GBGB9813561.9A GB9813561D0 (en) 1998-06-23 1998-06-23 Novel composition

Publications (1)

Publication Number Publication Date
ATE339223T1 true ATE339223T1 (de) 2006-10-15

Family

ID=26313263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914473T ATE339223T1 (de) 1998-03-09 1999-03-04 Kombinierte impfstoffzusammensetzungen

Country Status (22)

Country Link
US (2) US6451320B1 (de)
EP (1) EP1064025B1 (de)
JP (1) JP4510283B2 (de)
KR (1) KR20010041629A (de)
CN (1) CN1299288A (de)
AR (1) AR014684A1 (de)
AT (1) ATE339223T1 (de)
AU (1) AU750720B2 (de)
BR (1) BR9908599A (de)
CA (1) CA2324289C (de)
CO (1) CO4960659A1 (de)
DE (1) DE69933200T2 (de)
ES (1) ES2273482T3 (de)
HU (1) HUP0101047A3 (de)
IL (1) IL137998A0 (de)
MY (1) MY135965A (de)
NO (1) NO20004487L (de)
NZ (1) NZ506602A (de)
PL (1) PL343429A1 (de)
TR (1) TR200002608T2 (de)
TW (1) TW580393B (de)
WO (1) WO1999045957A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
CA2359110A1 (en) * 1999-01-12 2000-07-20 Ronald James Boon Combination of hepatitis b vaccine with antiviral agents
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
AU2003236490B2 (en) * 1999-09-07 2004-08-19 Smithkline Beecham Biologicals S.A. Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
KR100919916B1 (ko) * 2000-02-23 2009-10-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
US7811574B2 (en) 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0019728D0 (en) * 2000-08-10 2000-09-27 Smithkline Beecham Biolog Novel treatment
US20050238660A1 (en) * 2001-10-06 2005-10-27 Babiuk Lorne A Cpg formulations and related methods
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
KR100525321B1 (ko) * 2002-12-13 2005-11-02 안웅식 파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1513555A (zh) * 2003-07-31 2004-07-21 长春生物制品研究所 甲-乙型肝炎联合疫苗及其冻干制剂
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
DK1861120T3 (en) * 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
WO2008030560A2 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2484375T (pt) 2006-09-26 2018-07-09 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
CA2674051C (en) * 2006-12-28 2017-10-31 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2280728B1 (de) * 2008-05-26 2016-03-02 Cadila Healthcare Limited Kombinationsimpfstoff gegen masern- und humanpapillom-virus
KR101746872B1 (ko) * 2009-05-22 2017-06-14 제노시아 바이오사이언스, 인크. 단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법
SG176220A1 (en) 2009-05-27 2011-12-29 Glaxosmithkline Biolog Sa Casb7439 constructs
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
ES2651005T3 (es) * 2010-03-09 2018-01-23 Biomedical Research Models, Inc. Una nueva estrategia de vacunación mucosa para el virus del herpes simple tipo-2
WO2011150264A2 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
US9782474B2 (en) 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
WO2013006569A2 (en) * 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
DK2811981T3 (da) 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
US9555099B2 (en) 2012-05-16 2017-01-31 Immune Design Corp. Vaccines for HSV-2
US9566325B2 (en) 2013-01-07 2017-02-14 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type-2 infections
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
EP4058581A1 (de) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i-agonist und adjuvans-formulierung zur tumorbehandlung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
DE69131200T2 (de) * 1990-08-02 1999-12-09 Chiron Corp., Emeryville Herpes simplex virus vp16 impfstoffe
AU9052091A (en) * 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
JP3026029B2 (ja) * 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
EP0835663B1 (de) * 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
EP0609739A1 (de) * 1993-02-02 1994-08-10 American Cyanamid Company Methode der Umkehrung der Immunsuppression in Vakzinen
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
JP2002504080A (ja) * 1996-02-09 2002-02-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム 水痘―帯状疱疹ウィルス遺伝子６３産物に対するワクチン

Also Published As

Publication number Publication date
WO1999045957A2 (en) 1999-09-16
ES2273482T3 (es) 2007-05-01
MY135965A (en) 2008-07-31
PL343429A1 (en) 2001-08-13
HUP0101047A3 (en) 2004-10-28
EP1064025A2 (de) 2001-01-03
EP1064025B1 (de) 2006-09-13
DE69933200D1 (de) 2006-10-26
NO20004487L (no) 2000-10-19
US6932972B2 (en) 2005-08-23
WO1999045957A3 (en) 1999-11-25
TR200002608T2 (tr) 2000-11-21
HUP0101047A1 (hu) 2001-07-30
AR014684A1 (es) 2001-03-28
IL137998A0 (en) 2001-10-31
BR9908599A (pt) 2000-11-14
JP2002506045A (ja) 2002-02-26
JP4510283B2 (ja) 2010-07-21
US20030129199A1 (en) 2003-07-10
KR20010041629A (ko) 2001-05-25
NO20004487D0 (no) 2000-09-08
DE69933200T2 (de) 2007-02-22
CA2324289A1 (en) 1999-09-16
CN1299288A (zh) 2001-06-13
AU3328399A (en) 1999-09-27
CA2324289C (en) 2010-07-13
AU750720B2 (en) 2002-07-25
US6451320B1 (en) 2002-09-17
TW580393B (en) 2004-03-21
NZ506602A (en) 2003-02-28
CO4960659A1 (es) 2000-09-25

Similar Documents

Publication Publication Date Title
DE69933200D1 (de) Kombinierte impfstoffzusammensetzungen
NO20004758D0 (no) Vaksinesammensetning
ATE321569T1 (de) Kombinierte impfstoffzusammensetzungen
ATE490327T1 (de) Impfstoffzusammensetzung
ID26549A (id) Komposisi-komposisi epotilon
ATE367793T1 (de) Schweisshemmende zusammensetzungen
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
AR023440A1 (es) Composiciones antitranspirantes
NO20004240D0 (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
DE69900634D1 (de) Shampoozusammensetzungen
FI981011L (fi) Uudet koostumukset
IS5046A (is) Lyfjasamsetningar
ATE469550T1 (de) Antiparasitäre zusammensetzungen
EP1083926A4 (de) Impfstoff
DE69927758D1 (de) Imidosilan-Zusammensetzungen
ID29785A (id) Komposisi-komposisi sampo
DE60007731D1 (de) Schweisshemmende zusammensetzungen
ID27889A (id) Komposisi-komposisi kopolimer polisiklik
IS6398A (is) Lyfjablöndur
NO20005599L (no) Vaksine
EE200000459A (et) Farmatseutilised kompositsioonid
EE200100168A (et) Immunogeensed liposoomikompositsioonid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties